1 |
Gribben, J.G., Ryan, D.P., Boyajian, R., Urban, R.G., Hedley, M.L., Beach, K., Nealon, P., Matulonis, U., Campos, S., Gilligan, T.D., Richardson, P.G., Marshall, B., Neuberg, D. and Nadler, L.M. (2005) Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin. Cancer Res., 11, 4430-4436.
DOI
|
2 |
Shimada, T., Hayes, C.L., Yamazaki, H., Amin, S., Hecht, S.S., Guengerich, F.P. and Sutter, T.R. (1996) Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res., 56, 2979-2984.
|
3 |
Murray, G.I., Taylor, M.C., McFadyen, M.C., McKay, J.A., Greenlee, W.F., Burke, M.D. and Melvin, W.T. (1997) Tumorspecific expression of cytochrome P450 CYP1B1. Cancer Res., 57, 3026-3031.
|
4 |
Tsuchiya, Y., Nakajima, M., Kyo, S., Kanaya, T., Inoue, M. and Yokoi, T. (2004) Human CYP1B1 is regulated by estradiol via estrogen receptor. Cancer Res., 64, 3119-3125.
DOI
|
5 |
Goodin, M.G., Fertuck, K.C., Zacharewski, T.R. and Rosengren, R.J. (2002) Estrogen receptor-mediated actions of polyphenolic catechins in vivo and in vitro. Toxicol. Sci., 69, 354-361.
DOI
|
6 |
Nakajima, M., Iwanari, M. and Yokoi, T. (2003) Effects of histone deacetylation and DNA methylation on the constitutive and TCDD-inducible expressions of the human CYP1 family in MCF-7 and HeLa cells. Toxicol. Lett., 144, 247-256.
DOI
|
7 |
Heidel, S.M., Czuprynski, C.J. and Jefcoate, C.R. (1998) Bone marrow stromal cells constitutively express high levels of cytochrome P4501B1 that metabolize 7,12-dimethylbenz[a]anthracene. Mol. Pharmacol., 54, 1000-1006.
DOI
|
8 |
Chun, Y.J. and Kim, S. (2003) Discovery of cytochrome P450 1B1 inhibitors as new promising anti-cancer agents. Med. Res. Rev., 23, 657-668.
DOI
|
9 |
Yang, X., Zhang, B., Molony, C., Chudin, E., Hao, K., Zhu, J., Gaedigk, A., Suver, C., Zhong, H., Leeder, J.S., Guengerich, F.P., Strom, S.C., Schuetz, E., Rushmore, T.H., Ulrich, R.G., Slatter, J.G., Schadt, E.E., Kasarskis, A. and Lum, P.Y. (2010) Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver. Genome Res., 20, 1020-1036.
DOI
|
10 |
Nelson, D.R., Koymans, L., Kamataki, T., Stegeman, J.J., Feyereisen, R., Waxman, D.J., Waterman, M.R., Gotoh, O., Coon, M.J., Estabrook, R.W., Gunsalus, I.C. and Nebert, D.W. (1996) P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics, 6, 1-42.
DOI
|
11 |
Shimada, T. (2017) Inhibition of carcinogen-activating cytochrome P450 enzymes by xenobiotic chemicals in relation to antimutagenicity and anticarcinogenicity. Toxicol. Res., 33, 79-96.
DOI
|
12 |
Clevers, H. (2006) Wnt/ -catenin signaling in development and disease. Cell, 127, 469-480.
DOI
|
13 |
Saini, S., Hirata, H., Majid, S. and Dahiya, R. (2009) Functional significance of cytochrome P450 1B1 in endometrial carcinogenesis. Cancer Res., 69, 7038-7045.
DOI
|
14 |
Delvoux, B., Groothuis, P., D'Hooghe, T., Kyama, C., Dunselman, G. and Romano, A. (2009) Increased production of -estradiol in endometriosis lesions is the result of impaired metabolism. J. Clin. Endocrinol. Metab., 94, 876-883.
DOI
|
15 |
Chun, Y.J., Lee, S.K. and Kim, M.Y. (2005) Modulation of human cytochrome P450 1B1 expression by 2,4,3',5'-tetramethoxystilbene. Drug Metab. Dispos., 33, 1771-1776.
|
16 |
Zou, W., Papov, V., Malakhova, O., Kim, K.I., Dao, C., Li, J. and Zhang, D.E. (2005) ISG15 modification of ubiquitin E2 Ubc13 disrupts its ability to form thioester bond with ubiquitin. Biochem. Biophys. Res. Commun., 336, 61-68.
DOI
|
17 |
Piotrowska, H., Kucinska, M. and Murias, M. (2013) Expression of CYP1A1, CYP1B1 and MnSOD in a panel of human cancer cell lines. Mol. Cell. Biochem., 383, 95-102.
DOI
|
18 |
Barnett, J.A., Urbauer, D.L., Murray, G.I., Fuller, G.N. and Heimberger, A.B. (2007) Cytochrome P450 1B1 expression in glial cell tumors: an immunotherapeutic target. Clin. Cancer Res., 13, 3559-3567.
DOI
|
19 |
Akiyama, T. (2000) Wnt/ -catenin signaling. Cytokine Growth Factor Rev., 11, 273-282.
DOI
|
20 |
Konigshoff, M. and Eickelberg, O. (2010) WNT signaling in lung disease: a failure or a regeneration signal? Am. J. Respir. Cell Mol. Biol., 42, 21-31.
DOI
|
21 |
Kim, W., Kim, M. and Jho, E.H. (2013) Wnt/ -catenin signalling: from plasma membrane to nucleus. Biochem. J., 450, 9-21.
DOI
|
22 |
Lee, J., Li, L., Gretz, N., Gebert, J. and Dihlmann, S. (2012) Absent in Melanoma 2 (AIM2) is an important mediator of interferon-dependent and -independent HLA-DRA and HLADRB gene expression in colorectal cancers. Oncogene, 31, 1242-1253.
DOI
|
23 |
Narasimhan, J., Wang, M., Fu, Z., Klein, J.M., Haas, A.L. and Kim, J.J. (2005) Crystal structure of the interferon-induced ubiquitin-like protein ISG15. J. Biol. Chem., 280, 27356-27365.
DOI
|
24 |
Dastur, A., Beaudenon, S., Kelley, M., Krug, R.M. and Huibregtse, J.M. (2006) Herc5, an interferon-induced HECT E3 enzyme, is required for conjugation of ISG15 in human cells. J. Biol. Chem., 281, 4334-4338.
DOI
|
25 |
Shi, H.X., Yang, K., Liu, X., Liu, X.Y., Wei, B., Shan, Y.F., Zhu, L.H. and Wang, C. (2010) Positive regulation of interferon regulatory factor 3 activation by Herc5 via ISG15 modification. Mol. Cell. Biol., 30, 2424-2436.
DOI
|
26 |
Cruz, C., Ventura, F., Bartrons, R. and Rosa, J.L. (2001) HERC3 binding to and regulation by ubiquitin. FEBS Lett., 488, 74-80.
DOI
|
27 |
Skaug, B. and Chen, Z.J. (2010) Emerging role of ISG15 in antiviral immunity. Cell, 143, 187-190.
DOI
|
28 |
Durfee, L.A., Lyon, N., Seo, K. and Huibregtse, J.M. (2010) The ISG15 conjugation system broadly targets newly synthesized proteins: implications for the antiviral function of ISG15. Mol. Cell, 38, 722-732.
DOI
|
29 |
Hochrainer, K., Mayer, H., Baranyi, U., Binder, B., Lipp, J. and Kroismayr, R. (2005) The human HERC family of ubiquitin ligases: novel members, genomic organization, expression profiling, and evolutionary aspects. Genomics, 85, 153-164.
DOI
|
30 |
Wong, J.J., Pung, Y.F., Sze, N.S. and Chin, K.C. (2006) HERC5 is an IFN-induced HECT-type E3 protein ligase that mediates type I IFN-induced ISGylation of protein targets. Proc. Natl. Acad. Sci. U.S.A., 103, 10735-10740.
DOI
|
31 |
Kroismayr, R., Baranyi, U., Stehlik, C., Dorfleutner, A., Binder, B.R. and Lipp, J. (2004) HERC5, a HECT E3 ubiquitin ligase tightly regulated in LPS activated endothelial cells. J. Cell Sci., 117, 4749-4756.
DOI
|
32 |
Liu, C., Kato, Y., Zhang, Z., Do, V.M., Yankner, B.A. and He, X. (1999) -Trcp couples -catenin phosphorylation-degradation and regulates Xenopus axis formation. Proc. Natl. Acad. Sci. U.S.A., 96, 6273-6278.
DOI
|
33 |
Lee, J.H., Bae, J.A., Lee, J.H., Seo, Y.W., Kho, D.H., Sun, E.G., Lee, S.E., Cho, S.H., Joo, Y.E., Ahn, K.Y., Chung, I.J. and Kim, K.K. (2010) Glycoprotein 90K, downregulated in advanced colorectal cancer tissues, interacts with CD9/CD82 and suppresses the Wnt/ -catenin signal via ISGylation of -catenin. Gut, 59, 907-917.
DOI
|